IL5 and asthma: It is theoretically more effective than other IL-5 blockers which allow IL-5 independent migration of eosinophils into the tissue, although superior efficacy was not evident in clinical trials to date and the results of targeting the IL-5 axis seem broadly consistent with reduced exacerbation rates (rescue OCS ≥ 3 days) by approximately 50% and more modest improvements in symptoms and asthma-related quality of life measured and lung function (143).